Your browser doesn't support javascript.
loading
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Tarver, Theodore C; Hill, Jason E; Rahmat, Leena; Perl, Alexander E; Bahceci, Erkut; Mori, Kenichi; Smith, Catherine C.
Afiliação
  • Tarver TC; Division of Hematology-Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA.
  • Hill JE; Astellas Pharma US, Inc., Northbrook, IL.
  • Rahmat L; Division of Oncology-Hematologic Malignancies, Department of Medicine, Johns Hopkins University, Baltimore, MD.
  • Perl AE; Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA; and.
  • Bahceci E; Astellas Pharma US, Inc., Northbrook, IL.
  • Mori K; Astellas Pharma, Inc., Tokyo, Japan.
  • Smith CC; Division of Hematology-Oncology, Department of Medicine, University of California, San Francisco, San Francisco, CA.
Blood Adv ; 4(3): 514-524, 2020 02 11.
Article em En | MEDLINE | ID: mdl-32040554
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Tirosina Quinase 3 Semelhante a fms Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Tirosina Quinase 3 Semelhante a fms Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2020 Tipo de documento: Article